Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06581653
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-18
Brief Title:
Medication Adherence to Phone-supervised Pancreatic Enzyme Replacement Therapy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Medication Adherence to Phone-supervised Pancreatic Enzyme Replacement Therapya Prospective Randomized Clinical Trial
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to explore whether regular telephone intervention in patients with chronic pancreatitis can improve their Pancreatic Enzyme Replacement Therapys Medication Adherence
Detailed Description:
Pancreatic exocrine insufficiency PEI represents a significant complication in cases of chronic pancreatitis CP exerting considerable influence on patient quality-of-life outcomes The latest iteration 2020 from ACGs guidelines emphasizes Pancreatic Enzyme Replacement Therapy PERT as pivotal in managing both symptomatic and asymptomatic cases among individuals with CP PERT not only extends median survival but also substantially mitigates symptoms while averting digestive complications associated with malabsorption-ultimately enhancing overall well-being
An analysis revealed varying levels of PERT compliance across different patient groups-48 for those with CP 52 for pancreatic cancer sufferers and another 52 following pancreatic resection-induced PEI-with these rates declining to approximately 20 within one year post-initiation Furthermore findings from a limited-scale survey involving 148 individuals demonstrated that merely half exhibited satisfactory medication adherence notably attributed to inadequate comprehension regarding prescribed regimens
Presently lacking are established protocols aimed at bolstering PERT medication adherence specifically tailored towards individuals affected by CP-a gap this investigation seeks to address through comprehensive educational initiatives coupled with sustained telephonic interventions
An analysis revealed varying levels of PERT compliance across different patient groups-48 for those with CP 52 for pancreatic cancer sufferers and another 52 following pancreatic resection-induced PEI-with these rates declining to approximately 20 within one year post-initiation Furthermore findings from a limited-scale survey involving 148 individuals demonstrated that merely half exhibited satisfactory medication adherence notably attributed to inadequate comprehension regarding prescribed regimens
Presently lacking are established protocols aimed at bolstering PERT medication adherence specifically tailored towards individuals affected by CP-a gap this investigation seeks to address through comprehensive educational initiatives coupled with sustained telephonic interventions
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None